COM:PYXISONCOLOGY
Pyxis Oncology, Inc.
- Stock
Last Close
3.82
21/11 21:00
Market Cap
174.31M
Beta: -
Volume Today
15.04M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | 437K - | 437K 0% | ||||
average payables | 784K - | 6.51M 730.87% | 9.52M 46.21% | 5.50M 42.29% | ||
average receivables | 299K - | 309.50K 3.51% | ||||
book value per share | -0.13 - | -0.71 440.64% | 30.77 4,451.34% | 4.87 84.18% | 3.15 35.30% | |
capex per share | -0.07 - | -0.06 5.14% | -0.19 204.68% | -0.17 12.99% | ||
capex to depreciation | -3.16 - | -0.83 73.61% | -9.03 981.38% | -3.36 62.74% | ||
capex to operating cash flow | 0.15 - | 0.02 89.61% | 0.07 368.59% | 0.10 32.80% | ||
capex to revenue | ||||||
cash per share | 0.90 - | 0.37 59.24% | 32.35 8,758.10% | 5.43 83.22% | 3.03 44.24% | |
days of inventory on hand | ||||||
days payables outstanding | 711.02 - | |||||
days sales outstanding | ||||||
debt to assets | 0.00 - | 0.08 10,046.43% | 0.00 99.23% | 0.09 15,091.09% | 0.12 37.17% | |
debt to equity | -0.01 - | -0.05 855.24% | 0.00 101.27% | 0.12 18,532.46% | 0.17 44.23% | |
dividend yield | ||||||
earnings yield | -0.01 - | -0.04 375.60% | -0.88 1,902.79% | -2.66 204.50% | -1.03 61.45% | |
enterprise value | 270.40M - | 284.77M 5.31% | -181.40M 163.70% | -116.11M 35.99% | 82.02M 170.64% | |
enterprise value over ebitda | -93.92 - | -22.92 75.60% | 2.86 112.47% | 0.94 67.09% | -1.02 208.77% | |
ev to operating cash flow | -120.77 - | -28.24 76.62% | 5.13 118.18% | 1.30 74.69% | -1.16 189.25% | |
ev to sales | ||||||
free cash flow per share | -0.10 - | -0.52 413.08% | -4.22 707.79% | -2.90 31.37% | -1.94 33.04% | |
free cash flow yield | -0.01 - | -0.04 413.08% | -0.38 872.00% | -2.16 461.84% | -1.08 50.15% | |
graham net net | -0.14 - | -0.80 488.26% | 30.14 3,864.94% | 3.92 86.98% | 1.82 53.53% | |
graham number | 0.60 - | 3.03 407.08% | 81.52 2,591.20% | 19.78 75.74% | 11.45 42.11% | |
income quality | 0.81 - | 0.79 2.68% | 0.46 40.85% | 0.74 59.16% | 0.96 29.49% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0.14 Infinity% | |
interest coverage | 44.67 - | |||||
interest debt per share | 0.00 - | 0.04 5,064.47% | 0.02 44.89% | 0.49 2,417.69% | 0.53 9.29% | |
inventory turnover | ||||||
invested capital | -0.01 - | -0.05 855.24% | 0.00 101.27% | 0.12 18,532.46% | 0.17 44.23% | |
market cap | 290.07M - | 292.07M 0.69% | 93.17M 68.10% | 44.26M 52.49% | 71.83M 62.27% | |
net current asset value | -2.98M - | -17.69M 493.72% | 259.96M 1,569.31% | 136.06M 47.66% | 76.58M 43.71% | |
net debt to ebitda | 6.83 - | 0.59 91.40% | 4.32 636.12% | 1.30 69.97% | -0.13 109.79% | |
net income per share | -0.12 - | -0.58 375.60% | -9.60 1,564.44% | -3.57 62.80% | -1.85 48.21% | |
operating cash flow per share | -0.10 - | -0.46 347.30% | -4.16 812.64% | -2.70 34.98% | -1.77 34.48% | |
payables turnover | 0.51 - | |||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.13 - | -1.26 834.40% | -0.29 76.84% | -0.56 91.64% | -0.49 11.50% | |
revenue per share | ||||||
roe | 0.93 - | 0.82 12.03% | -0.31 138.25% | -0.73 135.06% | -0.59 19.96% | |
roic | 0.97 - | 0.91 6.42% | -0.29 131.40% | -0.61 112.38% | -0.49 19.02% | |
sales general and administrative to revenue | ||||||
shareholders equity per share | -0.13 - | -0.71 440.64% | 30.77 4,451.34% | 4.87 84.18% | 3.15 35.30% | |
stock based compensation to revenue | ||||||
tangible asset value | -2.87M - | -15.64M 444.36% | 261.31M 1,770.27% | 160.82M 38.46% | 101.40M 36.95% | |
tangible book value per share | -0.13 - | -0.71 440.64% | 30.77 4,451.34% | 4.87 84.18% | 2.54 47.81% | |
working capital | 18.97M - | 4.41M 76.73% | 259.96M 5,789.56% | 154.98M 40.39% | 98.84M 36.22% |
All numbers in (except ratios and percentages)